-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The International Cobweb Subcavity Aneurysm (ISAT) trial has resulted in a pattern shift from intracranial aneurysms to intravascular treatment, but it is not clear whether this reduces the risk of subcranial bleeding (aSAH) of aneurysm cobwebs.
, researchers tried to clarify the relationship between the burden of treatment of unbrobetered and ruptured aneurysms after ISAT, according to a recent study published in JAHA, an authoritative journal for cardiovascular disease.
researchers took hospital admission data from a national inpatient sample (2004-2014) and included patients who had been initially diagnosed with aSAH or an intracranial unbromed aneurysm, who received pruning or coiling therapy.
year, the combined group was randomly paired with a non-aneurysm control group based on age, gender, and Elixhauser combined index.
researchers performed polynotial regression to calculate the relative risk ratio of treatment for ruptured or unbromed aneurysm patients compared to the reference control group, and time-adjusted.
adjusting the results of the sample of national hospitalization samples, the researchers identified 243,754 cases of aneurysms, of which 174,580 (71.6%) were women and the average age was 55.4±13.2 years.
121,882 (50.01%) patients received treatment for unbromed aneurysms, 79,627 (65.3%) for in-vasovascular treatment and 42,256 (34.7%) for surgery.
121,872 (49.99%) patients underwent aSAH surgery, 68,921 (56.6%) received in-vasovascular surgery and 52,951 (43.5%) received surgical treatment. More than
regression analyses showed a significant reduction in annual aSAH surgery compared to the control group of non-aneurysm hospitalizations (with an annual relative risk ratio of 0.963; P-lt;0.001), while for unbromed aneurysm surgery, there was no statistical significance (the relative risk ratio per year was 1.012; P=0.35).
result, the relative risk ratio of aSAH treatment was significantly reduced over time, while the risk of treatment for patients with unbromed intracranial aneurysms was stable.